GUEST EDITORIAL

© 2025 Journal of Science Technology Education Art and Medicine DOI: 10.63137/jsteam.397801

OPEN C ACCESS

Global Challenges of Enteric Fever: Gaps, Hurdles, and Hope

Zeeshan Ahmed^a, Abdul Rehman^a, Osama Zulfiqar^b, Taha Rafiq^{c*}

- ^a King Edward Medical University, Pakistan
- ^b Rawalpindi Medical University, Pakistan
- ^c University of Galway, Ireland
- $\hbox{$*$Corresponding address: $University of $Galway$, $Ireland$}$

Email: taharafiq54@gmail.com

Received: 26 July 2025 / Available Online: 30 August 2025

This work is licensed under Creative Commons Attribution 4.0 International

Citation: Ahmed Z *et al.* Global challenges of enteric fever: Gaps, hurdles, and hope. *J Sci Technol Educ Art Med.* Published online August 30, 2025. doi:10.63137/jsteam.397801

Published online first: August 30, 2025

This article will appear in: J Sci Technol Educ Art Med, Volume 2, Issue 2 (December 2025)

Enteric fever, caused by *Salmonella enterica* serovars Typhi and Paratyphi, remains a pressing global health challenge. In 2021, the disease affected an estimated 9.3 million people and caused more than 100,000 deaths worldwide, with the greatest burden concentrated in South Asia and sub-Saharan Africa, particularly among children younger than five years. ¹ The clinical overlap with other febrile illnesses continues to complicate timely diagnosis. ² Simultaneously, the relentless spread of multidrug-resistant strains of *S. Typhi* threatens to erode existing treatment options and undermines global health security. ³

Despite decades of recognition, several entrenched challenges impede progress. Diagnostic capacity in endemic regions remains profoundly limited. ⁴ Blood culture, the current standard, suffers from poor sensitivity and requires infrastructure that is often absent. ⁵ Chronic carriers frequently go undetected, perpetuating community transmission. At the same time, antimicrobial resistance (AMR) has escalated sharply, diminishing the effectiveness of first-line antibiotics and leaving clinicians with dwindling therapeutic options.

Typhoid conjugate vaccines (TCVs) represent a scientific success story: they are safe, effective, and recommended by the World Health Organization (WHO) for use in endemic regions. ⁵ Yet, vaccine uptake lags far behind need. Delays in adoption are linked to competing health priorities, limited political will, weak immunization systems, and

inadequate public awareness. ^{6, 7} This mismatch between evidence and implementation highlights a systemic failure of global health governance.

The epidemiology of enteric fever is inextricably linked to structural inequities. Poor sanitation, unsafe water, and fragile health systems perpetuate transmission and hinder control. ⁸ Underinvestment is striking, relative to its burden, and enteric fever remains neglected in global health financing. While donor interest surges for high-profile epidemics, typhoid continues to struggle for visibility. These underfunding hampers diagnostics, vaccine rollout, and research into novel therapies.

Addressing enteric fever demands coordinated, multi-layered interventions. First, strengthening diagnostic infrastructure is imperative. Affordable, rapid diagnostic tests and molecular assays, alongside expanded access to blood cultures, would enable earlier detection and identification of asymptomatic carriers. Second. antimicrobial stewardship programs and urgent investment in new therapeutic development are required to counter the accelerating AMR crisis. 4 Third, widespread deployment of TCVs should be prioritized. ⁹ Evidence shows that routine infant immunization, combined with catch-up campaigns, is both highly cost-effective and capable of substantially reducing incidence. 10 Finally, sustainable improvements in water, sanitation, and hygiene (WASH) infrastructure are fundamental for long-term prevention.

National governments, multilateral agencies, and global health donors must act decisively. Endemic countries should integrate TCVs into routine immunization schedules without delay. International partners should provide financial and technical support for vaccine rollouts, laboratory strengthening, and WASH projects. Policymakers must also recognize that the fight against enteric fever is inseparable from broader goals of equity and health system resilience.

Further research, particularly into surveillance, novel diagnostics, and innovative therapies, remains critical. But evidence alone will not suffice. What is required is political commitment commensurate with the scale of the problem. Without urgent, coordinated action, the global community risks perpetuating a preventable disease that disproportionately affects the world's most vulnerable. With sustained investment and unified resolve, enteric fever can be controlled and ultimately consigned to history.

References

- 1. Piovani D, Figlioli G, Nikolopoulos GK, Bonovas S. The global burden of enteric fever, 2017–2021: a systematic analysis from the global burden of disease study 2021. eClinicalMedicine. 2024;77:102883.
- 2. Neupane DP, Dulal HP, Song J. Enteric Fever Diagnosis: Current Challenges and Future Directions. Pathogens. 2021;10(4):410.
- 3. Bisola Bello A, Olamilekan Adesola R, Idris I, Yawson Scott G, Alfa S, Akinfemi Ajibade F. Combatting extensively drugresistant Salmonella: a global perspective on outbreaks, impacts, and control strategies. Pathogens and Global Health. 2024;118(7-8):559-73.
- 4. Saha T, Arisoyin AE, Bollu B, Ashok T, Babu A, Issani A, et al. Enteric Fever: Diagnostic Challenges and the Importance of Early Intervention. Cureus. 2023;15(7):e41831.
- 5. Srinivasan M, Sindhu KN, Ramanujam K, Ramasamy RK, Subramaniam S, Ganesan SK, et al. Factors Predicting Blood Culture Positivity in Children With Enteric Fever. The Journal of infectious diseases. 2021;224(Supple 5):S484-s93.
- 6. Guillaume D, Meyer D, Waheed DE, Schlieff M, Muralidharan K, Chou VB, et al. Factors influencing the prioritization of vaccines by policymakers in low- and middle-income countries: a scoping review. Health policy and planning. 2023;38(3):363-76.
- 7. Ashraf MF, Daim SUR, Fayyaz H, Ashraf MA, Ashraf M. Navigating Pakistan's immunization landscape: Progress and pitfalls. IJID Regions. 2024;12:100382.
- 8. Ahmad S, Zahra J, Ali M, Ali S, Iqbal S, Kamal S, et al. Impact of water insecurity amidst endemic and pandemic in Pakistan: Two tales unsolved. Annals of Medicine and Surgery. 2022;81.
- 9. Gloeck NR, Leong TD, Mthethwa M, Iwu-Jaja CJ, Katoto PD, Wiysonge CS, et al. Typhoid conjugate vaccines for preventing typhoid fever (enteric fever). The Cochrane database of systematic reviews. 2025;5(5):Cd015746.
- 10. Chakraborty S, Das S. Typhoid & paratyphoid vaccine development in the laboratory: a review & in-country experience. The Indian journal of medical research. 2024;160(3&4):379-90.